National Guideline Clearinghouse | Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation.

full-text ►

National Guideline Clearinghouse | Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation.



National Institute for Health and Care Excellence (NICE)

Guideline Title

Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation.

Bibliographic Source(s)

National Institute for Health and Care Excellence. Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation. London (UK): National Institute for Health and Care Excellence; 2014 Apr. 57 p. (Technology appraisal guidance; no. 311).

Guideline Status

This is the current release of the guideline.